These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using Baum RP; Schuchardt C; Singh A; Chantadisai M; Robiller FC; Zhang J; Mueller D; Eismant A; Almaguel F; Zboralski D; Osterkamp F; Hoehne A; Reineke U; Smerling C; Kulkarni HR J Nucl Med; 2022 Mar; 63(3):415-423. PubMed ID: 34168013 [TBL] [Abstract][Full Text] [Related]
14. The inferior performance of [ Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850 [TBL] [Abstract][Full Text] [Related]
15. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics. Martin M; Ballal S; Yadav MP; Bal C; Van Rymenant Y; De Loose J; Verhulst E; De Meester I; Van Der Veken P; Roesch F Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980775 [TBL] [Abstract][Full Text] [Related]
16. Initial Clinical Experience with Ferdinandus J; Costa PF; Kessler L; Weber M; Hirmas N; Kostbade K; Bauer S; Schuler M; Ahrens M; Schildhaus HU; Rischpler C; Grafe H; Siveke JT; Herrmann K; Fendler WP; Hamacher R J Nucl Med; 2022 May; 63(5):727-734. PubMed ID: 34385340 [TBL] [Abstract][Full Text] [Related]
17. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886 [TBL] [Abstract][Full Text] [Related]
18. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930 [TBL] [Abstract][Full Text] [Related]
19. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
20. [ Ballal S; Yadav MP; Raju S; Roesch F; Martin M; Tripathi M; Bal C Nucl Med Mol Imaging; 2024 Feb; 58(1):32-34. PubMed ID: 38261876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]